Akari Therapeutics
Business Services · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
401 E Jackson St Ste 3300, Tampa, Florid...Phone Number
+44 2080040261Website
www.akaritx.comRevenue
-Stock Symbol
AKTXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Akari Therapeutics
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan, is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity. Nomacopan is currently being clinically evaluated in four areas: bullous pemphigoid (BP), thrombotic microangiopathy (TMA), as well as programs in the eye and lung.Explore more
Akari Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Akari Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Akari Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Akari Therapeutics launches new products
Check out if Akari Therapeutics is spiking on competitors!
Akari Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Akari Therapeutics has new funding data
Check if Akari Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Akari Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Akari Therapeutics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Akari Therapeutics
Compare insights from companies similar to Akari Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Akari Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Akari Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Akari Therapeutics.
Akari Therapeutics financials insights
Gather financial insights about Akari Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Share Placement
$4.5M
2020
Share Placement
$6M
Share Placement
$9.5M
2024
Share Placement
$2M
Share Placement
$7.6M
2026
Stock/Share Issuance
$5.5M
Akari Therapeutics Tech Stack
A closer look at the technologies used by Akari Therapeutics
See more technologies
Most Recent Scoops
Funding
Akari Therapeutics has secured $5.5 million in Share Issuance funding. Investors were not disclosed.
Funding
Project
Product Development, Product Management, Intellectual Property, Legal Affairs, Bioengineering, Pharmaceuticals
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Event
Events, Research & Development, Pharmaceuticals
Akari Therapeutics News & Media
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunities Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunitiesAkari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsAkari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined with an additional $2.8 million in proceeds from warrant exercises, results in approximately $8.3 million of capital received in Q2 2026, supporting future potential value inflection points Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined with an additional $2.8 million in proceeds from warrant exercises, results in approximately $8.3 million of capitalAkari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
Discussion highlights growing importance on novel ADC payloads, and Akari’s ASCO data in KRAS-driven cancers and future potential
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Akari Therapeutics
Sign Up For FreeTo access detailed company insights
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug... Read More
